Olaparib

ASCO issued a guideline update that recommends offering 1-year of adjuvant olaparib to certain patients with breast cancer.

Adavosertib alone and in combination with olaparib demonstrated efficacy among women with poly(ADP-ribose) polymerase (PARP) inhibitor-resistant ovarian cancer, according to study results presented during the virtual ASCO Annual Meeting.

One year of adjuvant olaparib significantly extended invasive and distant DFS among patients with high-risk, HER2-negative early-stage breast cancer and germline BRCA1/BRCA2 mutations, according to results of the phase 3 OlympiA study.

Olaparib maintenance significantly extended 5-year PFS for women with advanced BRCA-positive ovarian cancer, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The FDA approved the FoundationOne Liquid CDx test as a companion diagnostic device to help identify multiple additional biomarkers in cell-free DNA isolated from plasma, according to a press release from the agency.

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

Adding maintenance olaparib to bevacizumab provided a benefit beyond first progression, with a substantial second progression-free survival benefit, in patients with newly diagnosed, advanced high-grade ovarian carcinoma, according to data presented at ESMO Virtual Congress 2020.

After a 5-year follow-up, almost half of patients with newly diagnosed BRCA-mutated advanced ovarian cancer were progression-free after receiving 2 years of maintenance olaparib, according to data presented at ESMO Virtual Congress 2020.

Subsequent chemotherapy showed less efficacy in BRCA 1 and 2-mutated, platinum-sensitive, recurrent epithelial ovarian cancer treated with maintenance olaparib compared with placebo, according to a presentation at ESMO Virtual Congress 2020.

September is Gynecologic Cancer Awareness Month, an awareness campaign launched in 1999 by Foundation for Women’s Cancer.